Anti Cd 20 Ocrevus denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Applied a Quantity Limit — and Why You Can Appeal

Ocrelizumab (Ocrevus) is administered by intravenous infusion on a defined schedule established in the FDA-approved prescribing information. Humana's quantity-limit restrictions typically reflect that schedule — capping the number of vials, infusion sessions, or grams dispensed within a plan year. A denial fires when the quantity requested on the authorization does not match the plan's hard-coded allowance, even when the prescriber has ordered exactly what the label permits.

This type of denial is nearly always administrative rather than clinical: the insurer's system flags a mismatch between the submitted quantity and its internal table, without a physician reviewer evaluating your case. That makes it highly appealable.

## Your Federal Appeal Rights

• Internal appeal (Level 1): You have the right to a full-and-fair internal review under ERISA §503 (employer plans) or applicable state law (individual/group market plans). Submit within the timeframe on your denial notice — typically 180 days.
• External review (Level 2): Under ACA §2719 and its implementing regulations, you may request an independent external review from an accredited Independent Review Organization (IRO). The external-review window is generally four months from the date of final internal denial. For urgent clinical situations, expedited external review can return a binding decision within 72 hours.
• State insurance commissioner: If Humana's response violates your state's prompt-review standards, file a parallel complaint.

## Concrete Steps and Timeline

1. Request the denial letter in writing if you have not received it — it must state the specific quantity-limit rule applied and cite the coverage policy. 2. Obtain Humana's published Coverage Policy for ocrelizumab. Match every quantity parameter in that policy against the dosing schedule in the FDA-approved prescribing label for Ocrevus. 3. Submit your internal appeal within the deadline on the denial notice. Include the documentation package below. 4. If the internal appeal is denied or unanswered within the regulatory timeframe, file for external review immediately.

## Documentation to Gather

• Diagnosis confirmation: Neurologist's chart notes confirming diagnosis of relapsing or primary progressive multiple sclerosis, including subtype.
• Prescribing label alignment: A written statement from your neurologist explaining that the quantity requested matches the dosing regimen described in the FDA-approved prescribing information for Ocrevus — include the specific schedule the prescriber intends to follow.
• Prior infusion history: Dates, locations, and outcomes of any prior ocrelizumab infusions, showing the pattern is consistent with the approved schedule.
• Medical-necessity letter: A detailed letter from your neurologist explaining why the requested quantity over the plan year is medically necessary to maintain the therapeutic schedule, with reference to applicable MS society guidelines (e.g., the relevant American Academy of Neurology or National MS Society guidance).

## Criteria-Mapping Structure

Obtain the full text of Humana's quantity-limit coverage policy for ocrelizumab. For each requirement listed, pair it with the corresponding fact from your chart:

| Policy Requirement | Chart/Label Evidence | |---|---| | Approved indication (MS subtype) | [Neurologist diagnosis note, date] | | Quantity per dosing interval | [Prescriber order matching FDA label schedule] | | Maximum units per plan year | [Calculation showing requested quantity = label-defined annual doses] |

Precision in this mapping — showing that what was requested is exactly what the label authorizes — is the core of a successful quantity-limit appeal.